Premium
Long‐Circulating and Passively Tumor‐Targeted Polymer‐Drug Conjugates Improve the Efficacy and Reduce the Toxicity of Radiochemotherapy
Author(s) -
Lammers Twan,
Subr Vladimir,
Ulbrich Karel,
Peschke Peter,
Huber Peter E.,
Hennink Wim E.,
Storm Gert,
Kiessling Fabian
Publication year - 2010
Publication title -
advanced engineering materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.938
H-Index - 114
eISSN - 1527-2648
pISSN - 1438-1656
DOI - 10.1002/adem.200980046
Subject(s) - radiation therapy , gemcitabine , doxorubicin , prodrug , chemotherapy , drug , toxicity , medicine , cancer research , pharmacology , drug delivery , oncology , materials science , nanotechnology
Using HPMA copolymers as a model drug carrier, and doxorubicin and gemcitabine as model drugs, we here show that long‐circulating and passively tumor‐targeted polymeric drug carriers interact synergistically with radiotherapy, with radiotherapy improving the tumor accumulation of the copolymers, and with the copolymers improving both the efficacy and the toxicity of radiochemotherapy. These findings indicate that “carrier‐based radiochemotherapy” holds significant potential for improving the treatment of advanced solid malignancies.